CIC
KNTE

Cornercap Investment Counsel’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Cornercap Investment Counsel’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-68,040
Closed -$206K – 673
2023
Q2 		$206K Buy
+68,040
New +$262K 0.04% 506

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Cornercap Investment Counsel's KNTE Position: Q3 2023 in Review

Cornercap Investment Counsel sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q3 2023, closing a stake of 68,040 shares — an estimated $206K sold.

Cornercap Investment Counsel first reported a position in KNTE in Q2 2023 and held it in 1 quarter. The position peaked at $206K in Q2 2023. 58 funds tracked by Wall St. Rank hold KNTE as of Q3 2023.

  • Cornercap Investment Counsel reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Cornercap Investment Counsel sold 68,040 Kinnate Biopharma Inc. Common Stock shares in Q3 2023, an estimated $206K.
  • Cornercap Investment Counsel first reported a position in Kinnate Biopharma Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Cornercap Investment Counsel's Kinnate Biopharma Inc. Common Stock position peaked at $206K in Q2 2023.
  • 58 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q3 2023.

Based on Cornercap Investment Counsel's 13F filing for Q3 2023, filed 13 Nov 2023.